Metabolomic profiling in multiple sclerosis: Insights into biomarkers and pathogenesis

Multiple Sclerosis

Volumn 20, Issue 10, 2014, Pages 1396-1400

  Reinke, S N ^a   Broadhurst, D I ^a   Sykes, B D ^a   Baker, G B ^a   Catz, I ^a   Warren, K G ^a   Power, C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biomarker; Cerebrospinal fluid; Metabolomics; Multiple sclerosis; Nuclear magnetic resonance

Indexed keywords

2 HYDROXYBUTYRATE; 2 HYDROXYISOVALERATE; 3 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; CHOLINE; CITRIC ACID; CREATINE; CREATININE; FRUCTOSE; GLUCOSE; INOSITOL; LACTIC ACID; MANNOSE; PHENYLALANINE; THREONATE; TYROSINE; UNCLASSIFIED DRUG; PHOSPHOLIPID;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; ENERGY METABOLISM; FEMALE; HUMAN; MALE; METABOLOMICS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PHOSPHOLIPID METABOLISM; REPRODUCIBILITY; CASE CONTROL STUDY; CEREBROSPINAL FLUID; DEMYELINATING DISEASES; METABOLISM; MIDDLE AGED; MORTALITY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DEMYELINATING DISEASES; ENERGY METABOLISM; FEMALE; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84924043802     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513516528     Document Type: Article

References (15)

1. Compston A and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40: 387-426.
3. Lynch J, Peeling J, Auty A, et al. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci 1993; 20: 194-198.
4. Nicoli F, Vion-Dury J, Confort-Gouny S, et al. Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III 1996; 319: 623-631.
5. Simone IL, Federico F, Trojano M, et al. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 1996; 144: 182-190.
6. Aasly J, Garseth M, Sonnewald U, et al. Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol Scand 1997; 95: 9-12.
7. Lutz NW, Viola A, Malikova I, et al. Inflammatory multiplesclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One 2007; 2: e595.
8. Sinclair AJ, Viant MR, Ball AK, et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-a diagnostic tool? NMR Biomed 2010; 23: 123-132.
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127
10. Reinke SN, Resch L, Maingat F, et al. Metagenomic and metabolomic characterization of rabies encephalitis: New insights into the treatment of an ancient disease. J Infect Dis 2013; 207: 1451-1456.
11. Mandal R, Guo AC, Chaudhary KK, et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: A comprehensive and quantitative update. Genome Med 2012; 4: 38.
12. Benjamini Y and Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol 1995; 57: 289-300.
13. vVn Horssen J, Witte ME and Ciccarelli O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult Scler 2012; 18: 1058-1067.
14. Regenold WT, Phatak P, Makley MJ, et al. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 2008; 275: 106-112.
15. Rovira A and Alonso J. (1)H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am 2013; 23: 459-474.